About Adicet Bio
Adicet Bio is a publicly listed company based in Menlo Park (United States) founded in 2014. Immune cell therapies for cancer treatment are developed. Adicet Bio has raised $51 million across 5 funding rounds from investors including Regeneron Pharmaceuticals, HHS and Handok. The company has 152 employees. Adicet Bio has completed 1 acquisition, including Applied Immune Technologies. Its chief executive, as recorded, is Anil Singhal. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell. Its legal entity is ADICET BIO, INC. Its competitors include Poseida Therapeutics, Juno Therapeutics and TScan Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Adicet Bio was founded in 2014 and is headquartered in Menlo Park, United States. Operations focus on biotechnology, with immune cell therapeutic solutions developed for cancer and immune diseases. Universal immune cell therapies remain in pre-clinical stages, including ADI-001 targeting CD20 for lymphoma, ADI-002 targeting GPC3, and ADI-00x for solid tumors. Leadership is provided by CEO Anil Singhal.
- Headquarters Menlo Park, United States
- Employees 152
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website adicetbio.com
- Social LinkedIn X
- Legal Name Adicet Bio, Inc.
- Net Profit-$116.8 M (USD)0.27as on Dec 31, 2025
- EBITDA-$115.73 M (USD)4.47as on Dec 31, 2025
- Total Equity Funding$51M (USD)
in 5 rounds
- Latest Funding Round$15M (USD), Post-IPO
Feb 2021
- InvestorsRegeneron Pharmaceuticals
& 13 more
- Employee Count152
- Investments & Acquisitions
Funding Insights of Adicet Bio
Adicet Bio has successfully raised a total of $51M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $15 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $51M
- Total Rounds 5
- Last Round Post-IPO — $15M
- First Round $51M
(Jan 2016)
- Investors Count 14
All 5 funding rounds of Adicet Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $15M | Post-IPO | – | – | – |
| Oct 2019 | $80M | Post-IPO | – | aMoon, Regeneron Pharmaceuticals | |
| May 2019 | $2.19M | Grant | – | – | |
| Oct 2018 | $25.44M | Post-IPO | – | – | – |
| Jan 2016 | $51M | Series A | – | Orbimed |
14 investors in total: 14 institutional.
Investors in Adicet Bio
Adicet Bio has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Regeneron Pharmaceuticals, HHS and Handok.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in healthcare are focused on by aMoon. | amoon.fund | |||
Venture capital investments are made in promising startups. | 1999 | samsungventure.co.kr | Seocho, South Korea | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Pontifax Venture Capital is focused on life sciences investments. | pontifax.com | Herzeliya, Israel | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea | |
| sbi-ji.co.il | ||||
Early-stage venture capital is invested primarily in South Korean startups. | 2012 | dscinvestment.com | Seoul, South Korea | |
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Antibodies are developed for treating cancer, eye, and inflammatory diseases. | 1988 | regeneron.com | Tarrytown, United States |
Investor details for Adicet Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adicet Bio
72 people are tracked at Adicet Bio (30 in leadership, 13 in board & advisors, 29 in team); the tracked headcount is 152.
| Name | Role | Group |
|---|---|---|
Anil Singhal | CEO & President | Leadership |
Helen Budworth | Senior Director, Program Leadership And Program Management | Leadership |
Don Healey | CTO | Leadership |
Blake Aftab | Chief Scientific Officer | Leadership |
Soundarya Shanthappa | Associate Director Of Accounting, Assistant Controller | Leadership |
Jason Chan | Vice President, Quality Assurance | Leadership |
Chen Schor | President & CEO | Leadership |
Jyothi Sethuraman | Director | Leadership |
Nick Harvey | CFO | Leadership |
Scott Boyle | Director Of Quality And Validation | Leadership |
Sadaf S. | Director, Human Resources Business Partner | Leadership |
Diane Lee | Vice President, Controller | Leadership |
Gudrun Finn | Senior Director, Information Technology | Leadership |
Arun Bhat | Senior Director Molecular Engineering | Leadership |
Fernando Doñate | VP of Translational Medicine | Leadership |
Amy Locke | Head of Human Resources | Leadership |
Julie Maltzman | Chief Medical Officer | Leadership |
Hui Shao | Associate Director of Programs | Leadership |
Alison Chan | Sr. Director QA | Leadership |
Monica Moreno | Senior Director Translational Medicine | Leadership |
52 more people are available in the full profile.
Complete people profiles for Adicet Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Adicet Bio
Adicet Bio is a publicly listed company on the NASDAQ with ticker symbol ACET in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Dec 2025
- Listed onLSE: 0HX7
- Listed entityAdicet Bio, Inc.
- Exchange sectorHealth technology
Investments & Acquisitions by Adicet Bio
Adicet Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Applied Immune Technologies.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
TCRL antibodies are developed for therapeutic and diagnostic applications. | tcrl.co.il | Haifa, Israel | 2006 | Jan 2016 | •••• |
Complete acquisition details for Adicet Bio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Adicet Bio
5 dated milestones of Adicet Bio across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Adicet Bio is founded.
- Funding First funding round of $51.0M.
- Acquisition Acquires Applied Immune Technologies.
- Funding Latest funding round, Post-IPO, of $15.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Adicet Bio
Adicet Bio has 3 listed competitors in our database, 3 of them funded. They include Poseida Therapeutics, Juno Therapeutics and TScan Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. |
Detailed competitors of Adicet Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Adicet Bio
The website of Adicet Bio (adicetbio.com) receives about 5.1K visits a month and ranks #1,873,139 among all websites worldwide, #2,560 in Biotechnology and Pharmaceuticals.
- Monthly visits5.1K
▼ 51.8% vs previous month
- Unique visitors4.2K
per month
- Global rank#1,873,139
among all websites
- Category rank#2,560
Health · Biotechnology and Pharmaceuticals
- Bounce rate32%
- Pages per visit2.8
- Average visit1 min 10 sec
- DevicesDesktop 21% · Mobile 79%
Websites whose visitors overlap most with Adicet Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| oribiotech.com | 100% | 9.1K | #1,722,992 | View details | |
| trinitybiotech.com | 72% | 9.3K | #2,475,266 | View details |
Top companies in Cell Therapy
3 companies that operate in the same segment as Adicet Bio (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adicet Bio
Complete news archive for Adicet Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adicet Bio
Adicet Bio was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Adicet Bio is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Anil Singhal is the CEO of Adicet Bio, as recorded in our data.
Adicet Bio is a funded company, having raised a total of $51M across 5 funding rounds to date. The company's 1st funding round was a Series A of $51M, raised on Jan 2016.
Adicet Bio has 152 employees.
Adicet Bio was founded in 2014 and is headquartered in Menlo Park, United States. Operations focus on biotechnology, with immune cell therapeutic solutions developed for cancer and immune diseases. Universal immune cell therapies remain in pre-clinical stages, including ADI-001 targeting CD20 for lymphoma, ADI-002 targeting GPC3, and ADI-00x for solid tumors. Leadership is provided by CEO Anil Singhal.
Adicet Bio's top competitors include Juno Therapeutics, Poseida Therapeutics and TScan Therapeutics.
Yes, Adicet Bio is publicly traded on NASDAQ under the ticker symbol ACET.
Adicet Bio has made 1 acquisition, including Applied Immune Technologies.
Adicet Bio has 14 investors. Key investors include Regeneron Pharmaceuticals, HHS, Handok, Orbimed, and Samsung Venture Investment.
Adicet Bio operates through Adicet Bio, Inc..